Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 12/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 12/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4570450 | 0.87 | CCNE1 (0.58) | HSP90AA1HSP90AB1 | |
| Omaciclovir SCHEMBL14569460 | 0.86 | CCNE1 (0.43) | HDAC6HDAC1HDAC4 | |
| SCHEMBL31187469 | 0.84 | HDAC6 (0.49) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL2916968 | 0.84 | HDAC6 (0.49) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| Hydrochloric Acid SCHEMBL5930461 | 0.83 | HDAC6 (0.48) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL5513793 | 0.80 | HSP90AB1 (0.46) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL5513784 | 0.80 | HSP90AB1 (0.46) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL31058755 | 0.79 | HDAC6 (0.54) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| Acetic Acid SCHEMBL28553746 | 0.79 | CYP2C19 (0.48) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL10509135 | 0.79 | CCNE1 (0.41) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120123119-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-20120123119-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-8124609-B2 | Acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-8124609-B2 | Acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20090076041-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076041-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-7432274-B2 | Acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2008-10-07 | — | — | US | disclosed |
| US-7432274-B2 | Acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2008-10-07 | — | — | US | disclosed |
| US-7189849-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2007-03-13 | — | — | US | disclosed |
| US-7189849-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2007-03-13 | — | — | US | disclosed |
| US-5656617-A | ANTIVIRAL AGENT | MEDIVIR AB (SE) | 1997-08-12 | — | — | US | disclosed |
| US-5565461-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS | MEDIVIR AB (SE) | 1996-10-15 | — | — | US | disclosed |
| US-5284837-A | Viricides | MEDIVIR AB (SE) | 1994-02-08 | — | — | US | disclosed |
| EP-0343133-B1 | DERIVATIVES OF PURINE, PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL PREPARATION | Medivir Aktiebolag (SE) | 1992-04-08 | — | — | EP | disclosed |
| EP-0343133-A1 | Derivatives of purine, process for their preparation and a pharmaceutical preparation | Medivir Aktiebolag (SE) | 1989-11-23 | — | — | EP | disclosed |
| WO-1989010923-A1 | DERIVATIVES OF PURINE, PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL PREPARATION | MEDIVIR AB (SE) | 1989-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076041-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | NUDT1, PNP, NSUN2 | HDAC6 2601/4885HDAC1 720/4885HDAC4 2015/4885 |
| US-20120123119-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | NUDT1, PNP, NSUN2 | HDAC6 2548/4885HDAC1 720/4885HDAC4 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.